272. This AI Is Changing How We Treat Cancer—Personalized Medicine Explained

Love the podcast? Send us a text!What if your cancer treatment was designed just for you?In this episode of Breast Cancer Conversations, host Dr. Laura Carfang sits down with Jim Foote, CEO and co-founder of First Ascent Biomedical, to explore how AI-powered functional precision medicine is transforming cancer care.Instead of relying on one-size-fits-all treatment plans, this breakthrough approach tests your actual tumor cells against hundreds of FDA-approved drugs—revealing which therapies truly work for you and which don’t.🧬 You’ll learn:How functional precision medicine differs from genetic testingWhy AI and lab automation are revolutionizing oncologyReal-life patient stories of hope and survivalHow this technology cuts costs and reduces toxicityWhy personalization could become the new standard of care🎧 Tune in to hear how technology, compassion, and science are coming together to rewrite the future of cancer treatment.👉 Watch. Learn. Share. Because the future of oncology is personal.🔗 Resources & Links:SurvivingBreastCancer.orgFirst Ascent BiomedicalFollow us on Instagram: @SurvivingBreastCancerOrgListen on Apple Podcasts, Spotify, or wherever you get your podcasts💬 Join the conversation: What are your thoughts on personalized medicine? Leave a comment below and tell us how AI could change your cancer journey.Support the showListener FeedbackIf this episode resonated with you, we invite you to leave a review on Apple Podcasts or Spotify.You can also click the link in the show notes that says "Love this episode? Send us a text" to share feedback.Messages are completely anonymous.If you would like us to follow up directly, please include your email address in your message so we can respond.Latest News: Join our Mailing List - New content drops every Monday! Discover FREE programs, support groups, and resources from SurvivingBReastCancer.org! Become a Breast Cancer Conversations+ Member! Sign Up Now. Enjoying our content? Please consider supporting our work.